Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.](https://figures.cochat.ai/paper-figures/dfdd355eafec4c6e9c04f1a46b1d736c/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-1.jpg)
![Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.](https://figures.cochat.ai/paper-figures/1a6e539bef254c4eae8e1034fb2ebd96/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These preclinical studies demonstrated a significant reduction in collagen deposition (148).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [148]
In the citing paper
“Pharmacological inhibition of CCL2 by mNOX-E36 (121) or the use of cenicriviroc, a CCR2/CCR5 antagonist, gave promising anti-inflammatory and antifibrogenic results in mouse models (122).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAS, a histological tool developed to assess disease severity in humans, was assessed in a blinded fashion and calculated according to Kleiner’s criteria on H&E-stained sections [38].”
MethodChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 2×
“Fibrosis results from a sustained inflammatory response to chronic organ injury and is characterized by the deposition of extracellular matrix proteins, including collagen types 1 and 3 [1].”
BackgroundSelf-citationRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundFrom NAFLD to NASH to cirrhosis—new insights into disease mechanisms
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.149 · Cited by 609 · cited 1×
“NASH, a hepatic manifestation of the metabolic syndrome typically associated with insulin resistance, is the most serious form of highly prevalent NAFLD [46–48].”
BackgroundBaeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609 · cited 1×
“In turn, infiltrating monocytes/macrophages amplify this immune response by producing inflammatory cytokines and chemokines, which further promote recruitment of inflammatory cells and upregulate the activation of hepatic stellate cells (HSCs) [1,5].”
BackgroundSheth, S. G., Gordon, F. D., & Chopra, S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-2-199701150-00008 · Cited by 513
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503 · cited 3×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundCCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431 · cited 4×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundInfluentialGene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo
De Minicis, S., Seki, E., Uchinami, H., Kluwe, J., Zhang, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.033 · Cited by 426
CCR2 promotes hepatic fibrosis in mice #
Seki, E., de Minicis, S., Inokuchi, S., Taura, K., Miyai, K., van Rooijen, N., Schwabe, R. F., & Brenner, D. A. (2009) · Hepatology · doi:10.1002/hep.22952 · Cited by 416 · cited 4×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundInfluentialStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“These have different mechanisms of action to CVC, and include high-dose vitamin E, pioglitazone (peroxisome proliferator-activated receptor [PPAR]-gamma agonist), obeticholic acid (a farnesoid X receptor agonist) and elafibranor (formerly GFT505, a peroxisome proliferator-activated receptor-alpha/delta agonist) [50–52…”
BackgroundFujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355
Self-citationThe Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316 · cited 1×
“Hepatic fibrosis is associated with chronic liver disease, a significant global burden that contributes to cirrhosis and hepatocellular carcinoma [2].”
BackgroundRapid recruitment of inflammatory monocytes is independent of neutrophil migration
Henderson, R. B., Hobbs, J. A. R., Mathies, M., & Hogg, N. (2003) · Blood · doi:10.1182/blood-2002-10-3228 · Cited by 309
In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kanuri, G., & Bergheim, I. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611963 · Cited by 290
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Berres, M.-L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gassler, N., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41732 · Cited by 263 · cited 3×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundBlockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201248 · Cited by 254 · cited 1×
“Chemotaxis was assayed using a Transwell(1) Chamber (Costar, USA) with a 5 μm-pore size polycarbonate filter, as previously described [35].”
MethodSelf-citationCharacteristics and diagnosis of NAFLD/NASH
Hashimoto, E., Taniai, M., & Tokushige, K. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12271 · Cited by 248 · cited 1×
“NASH, a hepatic manifestation of the metabolic syndrome typically associated with insulin resistance, is the most serious form of highly prevalent NAFLD [46–48].”
BackgroundOverview of the cellular and molecular basis of kidney fibrosis
Eddy, A. A. (2014) · Kidney International Supplements · doi:10.1038/kisup.2014.2 · Cited by 242 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundTraber, P. G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.-I., & Friedman, S. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075361 · Cited by 214 · cited 1×
“The TAA model is commonly used for the evaluation of treatment at various stages of disease, from inflammation to cirrhosis [36].”
MethodSelf-citationFriedman, S., Sanyal, A., Goodman, Z., Lefebvre, E., Gottwald, M., Fischer, L., & Ratziu, V. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.02.012 · Cited by 197
Self-citationDual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice
Mitchell, C., Couton, D., Couty, J.-P., Anson, M., Crain, A.-M., Bizet, V., Rénia, L., Pol, S., Mallet, V., & Gilgenkrantz, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080632 · Cited by 189 · cited 3×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundUnilateral ureteral obstruction: beyond obstruction
Ucero, A. C., Benito-Martin, A., Izquierdo, M. C., Sanchez-Niño, M. D., Sanz, A. B., Ramos, A. M., Berzal, S., Ruiz-Ortega, M., Egido, J., & Ortiz, A. (2014) · International Urology and Nephrology · doi:10.1007/s11255-013-0520-1 · Cited by 189 · cited 1×
“Unilateral ureter obstruction is a commonly used experimental model of kidney injury, in which interstitial inflammation, tubular cell injury/death and fibrosis, ensue [32].”
BackgroundThe Role of Chemokines in Acute Liver Injury
Saiman, Y., & Friedman, S. L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00213 · Cited by 180 · cited 4×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundInfluentialSelf-citationVIELHAUER, V., ANDERS, H.-J., MACK, M., CIHAK, J., STRUTZ, F., STANGASSINGER, M., LUCKOW, B., GRO[Combining Diaeresis]NE, H.-J., & SCHLO[Combining Diaeresis]NDORFF, D. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261173 · Cited by 177
Expression of the C-C chemokine receptor 5 in human kidney diseases
Segerer, S., Mack, M., Regele, H., Kerjaschki, D., & Schlöndorff, D. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00544.x · Cited by 170
Piazzon, M. C., Savelkoul, H. F. J., Pietretti, D., Wiegertjes, G. F., & Forlenza, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402093 · Cited by 136
Zimmermann, H. W., & Tacke, F. (2011) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152811798104890 · Cited by 124 · cited 5×
“Hepatocytes, KCs and infiltrating monocytes/macrophages are the main sources of TGF-beta, a major fibrogenic cytokine promoting collagen production by activated HSCs [12].”
BackgroundInfluentialKang, Y. S., Lee, M., Song, H. K., Ko, G. J., Kwon, O. S., Lim, T. K., Kim, S. H., Han, S. Y., Han, K. H., Lee, J. E., et al. (2010) · Kidney International · doi:10.1038/ki.2010.263 · Cited by 122 · cited 1×
“Additional evidence substantiates the roles of CCR2/CCR5 and their ligands in renal fibrosis [16–20].”
BackgroundBaba, M., Takashima, K., Miyake, H., Kanzaki, N., Teshima, K., Wang, X., Shiraishi, M., & Iizawa, Y. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4584-4591.2005 · Cited by 111
Thompson, M., Saag, M. S., DeJesus, E., Gathe, J., Lalezari, J. P., LANDAY, A. L., Cade, J. L., Enejosa, J., Lefebvre, E. A., & Feinberg, J. (2015) · AIDS · doi:10.1097/qad.0000000000000988 · Cited by 91
Self-citationAnimal models for the study of liver fibrosis: new insights from knockout mouse models
Hayashi, H., & Sakai, T. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00013.2011 · Cited by 88 · cited 1×
“A number of in vitro and in vivomodels of fibrosis are commonly used to assess recruitment of inflammatory cells and antifibrotic activity of therapeutic agents [31–33].”
BackgroundDing, S.-Y., Shen, Z., Chen, Y.-T., Sun, S., Liu, Q., & Xie, M. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00090.x · Cited by 67 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundLalezari, J., Gathe, J., Brinson, C., Thompson, M., Cohen, C., Dejesus, E., Galindez, J., Ernst, J. A., Martin, D. E., & Palleja, S. M. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318213c2c0 · Cited by 64 · cited 1×
“In addition, CVC exhibited a good tolerability profile in humans, including hepatically impaired subjects [21,25,26].”
BackgroundSelf-citationLefebvre, E. A., Gottwald, M. D., Lasseter, K. C., Chang, W., Willett, M. S., Smith, P. F., Somasunderam, A., & Utay, N. S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12397 · Cited by 59
Self-citationKidney Diseases and Chemokines
Panzer, U., Steinmetz, O. M., Stahl, R. A. K., & Wolf, G. (2006) · Current Drug Targets · doi:10.2174/138945006775270213 · Cited by 57 · cited 1×
“Additional evidence substantiates the roles of CCR2/CCR5 and their ligands in renal fibrosis [16–20].”
BackgroundCCR2 Regulates the Uptake of Bone Marrow-Derived Fibroblasts in Renal Fibrosis
Xia, Y., Entman, M. L., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077493 · Cited by 46 · cited 1×
“Additional evidence substantiates the roles of CCR2/CCR5 and their ligands in renal fibrosis [16–20].”
BackgroundMarier, J., Trinh, M. M., Pheng, L. H., Palleja, S. M., & Martin, D. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00713-10 · Cited by 43 · cited 1×
“Cenicriviroc (CVC) is a novel, oral, once-daily (QD) dual CCR2/CCR5 antagonist with nanomolar potency, and a long plasma half-life (30–40 hours in humans) [21–24].”
BackgroundAdditive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice
Higashi, K., Oda, T., Kushiyama, T., Hyodo, T., Yamada, M., Suzuki, S., Sakurai, Y., Miura, S., & Kumagai, H. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01253.x · Cited by 28 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundPPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
Han, J.-Y., Kim, Y.-J., Kim, L., Choi, S. J., Park, I.-S., Kim, J. M., Chu, Y. C., & Cha, D.-R. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.1.35 · Cited by 26 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundPuengel, T., Krenkel, O., Mossanen, J. C., Longerich, T., Lefebvre, E. A., Trautwein, C., & Tacke, F. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)01667-6 · Cited by 10
Self-citationByron, M. M., D’Antoni, M. L., Premeaux, T. A., Lefebvre, E. A., & Ndhlovu, L. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.194.supp.187.8 · Cited by 4
Self-citationKrenkel, O., Mossanen, J. C., Ergen, C., Heymann, F., Lefebvre, E., Eulberg, D., Trautwein, C., & Tacke, F. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30041-6 · Cited by 2
Self-citation
Research works printed but not linked: 3
- Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
- MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
- M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citationLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Significant decrease in lobular inflammation, hepatocellular ballooning as well as collagen 1 and α-SMA protein expression in NASH mouse model [334].”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923
Metadata
- Authors
- Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- AIDS Research Consortium of Atlanta (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stelic (Japan) (JP)
- Charles River Laboratories (Canada) (CA)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-27
- Volume
- 11
- Issue
- 6
- Pages
- e0158156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4922569
- OpenAlex
- W2467384826
- Cited by
- 323
- References
- 51
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute of General Medical Sciences (T32GM007170)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
- MeSH terms
- Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.